Inventor

SCHILTZ GARY E

US22 patents

Patents

22 patents

US9981968B2May 29, 2018

Substituted pyrrolo[2,3-d]pyrimidines for the treatment of cancer and proliferative disorders

UNIV NORTHWESTERN14 citations79

US10435375B2Oct 8, 2019

CXCR4 chemokine receptor modulators

UNIV NORTHWESTERN4 citations72

US10640502B2May 5, 2020

Therapeutic targeting of interleukin-1 receptor-associated kinase 4 (IRAK4) in cancers characterized by rearrangements in the mixed lineage leukemia gene (MLL-r)

UNIV NORTHWESTERN3 citations68

US10093668B2Oct 9, 2018

Substituted aromatic N-heterocyclic compounds as inhibitors of mitogen-activated protein kinase interacting kinase 1 (Mnk1) and 2 (Mnk2)

UNIV NORTHWESTERN5 citations68

US9669014B2Jun 6, 2017

Small molecule inhibitors of superoxide dismutase expression

UNIV NORTHWESTERN3 citations66

US10851082B2Dec 1, 2020

Substituted aromatic n-heterocyclic compounds as inhibitors of mitogen-activated protein kinase interacting kinase 1 (MNK1) and 2 (MNK2)

UNIV NORTHWESTERN2 citations64

US12252492B2Mar 18, 2025

Substituted fused pyrrolo-diazepinones and uses thereof

UNIV NORTHWESTERN0 citations62

US11225483B2Jan 18, 2022

Substituted fused pyrrolo-diazepinones and uses thereof

UNIV NORTHWESTERN1 citations62

US12492209B2Dec 9, 2025

Substituted [1,2,4]triazolo[4,3-c]pyrimidines that induce degradation of embryonic ectoderm development (EED) protein

UNIV NORTHWESTERN0 citations60

US12491252B2Dec 9, 2025

Substituted 3-amino-5-phenylbenzamide compounds as covalent inhibitors of enhancer zeste homolog 2 (EZH2) and proteolysis-targeting chimeric derivatives thereof (PROTACs) that induce degradation of EZH2

UNIV NORTHWESTERN0 citations60

US12042543B2Jul 23, 2024

Substituted 3-amino-5-phenylbenzamide compounds as covalent inhibitors of enhancer zeste homolog 2 (EZH2) and proteolysis-targeting chimeric derivatives thereof (PROTACs) that induce degradation of EZH2

UNIV NORTHWESTERN0 citations60

US11981678B2May 14, 2024

Substituted [1,2,4]triazolo[4,3-c]pyrimidin-5-amines and proteolysis-targeting chimeric derivatives thereof (PROTACs) that induce degradation of embryonic ectoderm development (EED) protein

UNIV NORTHWESTERN0 citations60

US9688637B2Jun 27, 2017

3-amidobenzamides and uses thereof for increasing cellular levels of A3G and other A3 family members

UNIV NORTHWESTERN3 citations59

US11890346B2Feb 6, 2024

Proteolysis-targeting chimeric molecules (PROTACs) that induce degradation of c-MYC protein

UNIV NORTHWESTERN0 citations58

US11453640B2Sep 27, 2022

Small molecules for disrupting the super elongation complex and inhibiting transcription elongation for cancer therapy

UNIV NORTHWESTERN0 citations57

US12311029B2May 27, 2025

Proteolysis-targeting chimeric molecules (PROTACs) that induce degradation of indoleamine 2,3-dioxygenase (IDO) protein

UNIV NORTHWESTERN0 citations54

US11839659B2Dec 12, 2023

Proteolysis-targeting chimeric molecules (PROTACs) that induce degradation of indoleamine 2,3-dioxygenase (IDO) protein

UNIV NORTHWESTERN0 citations54

US11370770B2Jun 28, 2022

3-arylindazoles as selective MEK4 inhibitors

UNIV NORTHWESTERN0 citations54

US11919855B2Mar 5, 2024

Substituted pyrrolidones and piperidones as small molecule inhibitors of EZH2 and EED protein binding

UNIV NORTHWESTERN0 citations49

US11420957B2Aug 23, 2022

SCHILTZ GARY E

Patents

Substituted pyrrolo[2,3-d]pyrimidines for the treatment of cancer and proliferative disorders

CXCR4 chemokine receptor modulators

Therapeutic targeting of interleukin-1 receptor-associated kinase 4 (IRAK4) in cancers characterized by rearrangements in the mixed lineage leukemia gene (MLL-r)

Substituted aromatic N-heterocyclic compounds as inhibitors of mitogen-activated protein kinase interacting kinase 1 (Mnk1) and 2 (Mnk2)

Small molecule inhibitors of superoxide dismutase expression

Substituted aromatic n-heterocyclic compounds as inhibitors of mitogen-activated protein kinase interacting kinase 1 (MNK1) and 2 (MNK2)

Substituted fused pyrrolo-diazepinones and uses thereof

Substituted fused pyrrolo-diazepinones and uses thereof

Substituted [1,2,4]triazolo[4,3-c]pyrimidines that induce degradation of embryonic ectoderm development (EED) protein

Substituted 3-amino-5-phenylbenzamide compounds as covalent inhibitors of enhancer zeste homolog 2 (EZH2) and proteolysis-targeting chimeric derivatives thereof (PROTACs) that induce degradation of EZH2

Substituted 3-amino-5-phenylbenzamide compounds as covalent inhibitors of enhancer zeste homolog 2 (EZH2) and proteolysis-targeting chimeric derivatives thereof (PROTACs) that induce degradation of EZH2

Substituted [1,2,4]triazolo[4,3-c]pyrimidin-5-amines and proteolysis-targeting chimeric derivatives thereof (PROTACs) that induce degradation of embryonic ectoderm development (EED) protein

3-amidobenzamides and uses thereof for increasing cellular levels of A3G and other A3 family members

Proteolysis-targeting chimeric molecules (PROTACs) that induce degradation of c-MYC protein

Small molecules for disrupting the super elongation complex and inhibiting transcription elongation for cancer therapy

Proteolysis-targeting chimeric molecules (PROTACs) that induce degradation of indoleamine 2,3-dioxygenase (IDO) protein

Proteolysis-targeting chimeric molecules (PROTACs) that induce degradation of indoleamine 2,3-dioxygenase (IDO) protein

3-arylindazoles as selective MEK4 inhibitors

Substituted pyrrolidones and piperidones as small molecule inhibitors of EZH2 and EED protein binding

Substituted heterocycles as c-MYC targeting agents

Substituted heterocycles as c-MYC targeting agents

Substituted heterocycles as c-MYC targeting agents